Repligen Corporation (RGEN)
NASDAQ: RGEN · Real-Time Price · USD
158.99
-3.68 (-2.26%)
Feb 21, 2025, 4:00 PM EST - Market closed
Repligen Employees
Repligen had 1,783 employees as of December 31, 2023. The number of employees decreased by 242 or -11.95% compared to the previous year.
Employees
1,783
Change (1Y)
-242
Growth (1Y)
-11.95%
Revenue / Employee
$355,827
Profits / Employee
-$14,310
Market Cap
8.91B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 1,783 | -242 | -11.95% |
Dec 31, 2022 | 2,025 | 173 | 9.34% |
Dec 31, 2021 | 1,852 | 724 | 64.18% |
Dec 31, 2020 | 1,128 | 367 | 48.23% |
Dec 31, 2019 | 761 | 213 | 38.87% |
Dec 31, 2018 | 548 | 72 | 15.13% |
Dec 31, 2017 | 476 | 240 | 101.69% |
Dec 31, 2016 | 236 | 68 | 40.48% |
Dec 31, 2015 | 168 | 32 | 23.53% |
Dec 31, 2014 | 136 | 20 | 17.24% |
Dec 31, 2013 | 116 | -4 | -3.33% |
Dec 31, 2012 | 120 | -17 | -12.41% |
Dec 31, 2011 | 137 | 69 | 101.47% |
May 6, 2010 | 68 | -1 | -1.45% |
May 31, 2009 | 69 | 13 | 23.21% |
May 27, 2008 | 56 | 11 | 24.44% |
Jun 30, 2007 | 45 | 2 | 4.65% |
Jun 6, 2006 | 43 | 6 | 16.22% |
Jun 7, 2005 | 37 | -3 | -7.50% |
Jun 7, 2004 | 40 | -4 | -9.09% |
May 15, 2003 | 44 | 5 | 12.82% |
May 15, 2002 | 39 | -1 | -2.50% |
May 15, 2001 | 40 | 13 | 48.15% |
May 15, 2000 | 27 | 3 | 12.50% |
May 15, 1999 | 24 | 0 | - |
May 29, 1998 | 24 | 4 | 20.00% |
May 15, 1997 | 20 | 5 | 33.33% |
Jun 14, 1996 | 15 | -89 | -85.58% |
Mar 31, 1995 | 104 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 440,000 |
Johnson & Johnson | 131,900 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 72,000 |
RGEN News
- 2 days ago - Repligen Corporation (RGEN) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 2 days ago - Repligen Q4 Earnings Momentum Highlights Market Growth, Issues Strong 2025 Outlook - Benzinga
- 11 days ago - Repligen to Report Fourth Quarter and Full Year 2024 Financial Results - GlobeNewsWire
- 6 weeks ago - Repligen Corporation to Present at 43rd Annual J.P. Morgan Healthcare Conference - GlobeNewsWire
- 6 weeks ago - Repligen Launches the CTech™ SoloVPE® PLUS System - GlobeNewsWire
- 2 months ago - BioLife Solutions Appoints Tony J. Hunt to its Board of Directors - PRNewsWire
- 2 months ago - Repligen Announces Publication of the Company's 2023 Corporate Sustainability Report - GlobeNewsWire
- 2 months ago - Repligen Launches Novel AVIPure® dsRNA Resin in OPUS® Pre-packed Columns - GlobeNewsWire